Funding news · Nov 19, 2026

Arkana Therapeutics Raises $3M Pre-Seed for Oral Obesity and Metabolic Therapies

Arkana Therapeutics, a Boulder, Colorado-based biotech, has raised a $3 million pre-seed round. The round was funded by Boulder Angels, with no lead investor disclosed.

Company Background

Arkana Therapeutics was spun out of the lab of Leslie Leinwand at the University of Colorado Boulder. The company is developing oral small-molecule therapies for obesity and metabolic disease.

Arkana was co-founded in 2025 by CEO Jack Gugel alongside Leinwand, Thomas Martin and Jonathan Long of Stanford.

The Science

Arkana's approach is inspired by python biology. After a large meal, Burmese pythons flood their blood with a metabolite that rises roughly 1,000-fold and acts as a natural appetite suppressant. Arkana is working to turn that biology into medicines that reduce calorie intake and raise energy expenditure through mechanisms beyond GLP-1.

Pipeline

The company is advancing two oral pipeline programs:

  • ARK-100 — focused on appetite suppression
  • ARK-200 — focused on energy expenditure

Deal Summary

  • Company: Arkana Therapeutics
  • Headquarters: Boulder, Colorado
  • Stage: Pre-Seed
  • Round type: Pre-Seed
  • Amount: $3,000,000 USD
  • Funding date: November 19, 2026
  • Investors: Boulder Angels
  • Lead investor: Not disclosed

Why It Matters

Arkana sits at the intersection of two active areas in metabolic drug development: oral small-molecule formats and mechanisms that extend beyond the GLP-1 pathway. Its two-program pipeline targets both sides of the energy balance equation — how much is consumed and how much is expended — using biology observed in a natural model of extreme metabolic adaptation.

The pre-seed funding provides capital as the company advances ARK-100 and ARK-200, both oral programs, out of its University of Colorado Boulder research roots.

© 2026 VeilStrat. All rights reserved.All systems operational